BACKGROUND: This Phase I study assessed the safety and maximum tolerated dose (MTD) of the kinesin spindle protein inhibitor AZD4877 in patients with relapsed/refractory solid tumors and lymphoma. METHODS: In this multicenter study, a standard 3 + 3 dose-escalation design was used. AZD4877 was given as an intravenous infusion on days 1, 4, 8 and 11 of each 21-day cycle. Responses were assessed with CT scans +/- PET after 6 and 12 weeks, then every 12 weeks while on therapy. An additional four patients with lymphoma were enrolled at the MTD. RESULTS: 29 patients were enrolled and 22 patients received at least one dose of AZD4877 and were evaluable for safety. The MTD was 11 mg. Dose-limiting toxicity was neutropenia (n = 2 patients, 15 mg cohort). The most common adverse events were grade 1/2 fatigue, nausea, neutropenia and dyspnea. AZD4877 exposure generally increased with dose, with mean elimination half-life approximately 16 h at the MTD. Pharmacodynamic analyses demonstrated moderate correlation between plasma drug concentrations at 6 or 24 h and monoaster formation in peripheral blood mononuclear cells (PBMCs). CONCLUSIONS: AZD4877 is generally well-tolerated with pharmacodynamic evidence of target inhibition in circulating PBMCs.
BACKGROUND: This Phase I study assessed the safety and maximum tolerated dose (MTD) of the kinesin spindle protein inhibitor AZD4877 in patients with relapsed/refractory solid tumors and lymphoma. METHODS: In this multicenter study, a standard 3 + 3 dose-escalation design was used. AZD4877 was given as an intravenous infusion on days 1, 4, 8 and 11 of each 21-day cycle. Responses were assessed with CT scans +/- PET after 6 and 12 weeks, then every 12 weeks while on therapy. An additional four patients with lymphoma were enrolled at the MTD. RESULTS: 29 patients were enrolled and 22 patients received at least one dose of AZD4877 and were evaluable for safety. The MTD was 11 mg. Dose-limiting toxicity was neutropenia (n = 2 patients, 15 mg cohort). The most common adverse events were grade 1/2 fatigue, nausea, neutropenia and dyspnea. AZD4877 exposure generally increased with dose, with mean elimination half-life approximately 16 h at the MTD. Pharmacodynamic analyses demonstrated moderate correlation between plasma drug concentrations at 6 or 24 h and monoaster formation in peripheral blood mononuclear cells (PBMCs). CONCLUSIONS:AZD4877 is generally well-tolerated with pharmacodynamic evidence of target inhibition in circulating PBMCs.
Authors: J R Infante; R Kurzrock; J Spratlin; H A Burris; S G Eckhardt; J Li; K Wu; J M Skolnik; L Hylander-Gans; A Osmukhina; D Huszar; R S Herbst Journal: Cancer Chemother Pharmacol Date: 2011-06-03 Impact factor: 3.333
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Youwei Yan; Vinod Sardana; Bei Xu; Carl Homnick; Wasyl Halczenko; Carolyn A Buser; Michael Schaber; George D Hartman; Hans E Huber; Lawrence C Kuo Journal: J Mol Biol Date: 2004-01-09 Impact factor: 5.469
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Kyle Holen; Robert DiPaola; Glenn Liu; Antoinette R Tan; George Wilding; Karl Hsu; Nancy Agrawal; Cong Chen; Lingling Xue; Elizabeth Rosenberg; Mark Stein Journal: Invest New Drugs Date: 2011-03-22 Impact factor: 3.850
Authors: Kyle D Holen; Chandra P Belani; George Wilding; Suresh Ramalingam; Jennifer L Volkman; Ramesh K Ramanathan; Lakshmi S Vasist; Carolyn J Bowen; Jeffrey P Hodge; Mohammed M Dar; Peter T C Ho Journal: Cancer Chemother Pharmacol Date: 2010-05-12 Impact factor: 3.333
Authors: A Hollebecque; E Deutsch; C Massard; C Gomez-Roca; R Bahleda; V Ribrag; C Bourgier; V Lazar; L Lacroix; A Gazzah; A Varga; T de Baere; F Beier; S Kroesser; K Trang; F T Zenke; M Klevesath; Jean-Charles Soria Journal: Invest New Drugs Date: 2013-12 Impact factor: 3.850